|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 319.00 SEK | -3.10% |
|
-1.17% | +3.60% |
| 08/05 | US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy | MT |
| 08/05 | Futures point to negative opening for Stockholm Stock Exchange (update) | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 85Cr | 81Cr | 61Cr | 51Cr | 104.04Cr | |||||
Short Term Investments | - | - | 50Cr | 27Cr | 115Cr | |||||
Total Cash And Short Term Investments | 85Cr | 81Cr | 111.16Cr | 78Cr | 219.04Cr | |||||
Accounts Receivable, Total | 28.39L | - | 2L | 7.12Cr | 12Cr | |||||
Other Receivables | 62.05L | 79.56L | 3.15Cr | 14Cr | 17Cr | |||||
Total Receivables | 90.44L | 79.56L | 3.18Cr | 21Cr | 29Cr | |||||
Prepaid Expenses | 43.37L | 74.98L | 94.02L | 1.82Cr | 96.15L | |||||
Other Current Assets, Total | - | 1T | -1T | - | - | |||||
Total Current Assets | 86Cr | 82Cr | 115.27Cr | 101.07Cr | 248.7Cr | |||||
Gross Property Plant And Equipment | 8.22Cr | 9.79Cr | 11Cr | 16Cr | 17Cr | |||||
Accumulated Depreciation | -4.85Cr | -6.27Cr | -7.73Cr | -6.17Cr | -8.94Cr | |||||
Net Property Plant And Equipment | 3.37Cr | 3.53Cr | 3.11Cr | 9.66Cr | 8.3Cr | |||||
Deferred Tax Assets Long-Term | 6L | 6L | 6L | 10L | 14.55L | |||||
Other Long-Term Assets, Total | 15.88L | 16.06L | 16.48L | 34.41L | 38.33L | |||||
Total Assets | 90Cr | 86Cr | 118.61Cr | 111.17Cr | 257.52Cr | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 1.18Cr | 2.15Cr | 2.99Cr | 5.05Cr | 2.39Cr | |||||
Accrued Expenses, Total | 1.83Cr | 3.51Cr | 4.88Cr | 6.83Cr | 33Cr | |||||
Current Portion of Leases | 80.92L | 88.57L | 28.27L | 1.31Cr | 1.57Cr | |||||
Current Income Taxes Payable | - | - | 3.38Cr | 3.36Cr | 14Cr | |||||
Unearned Revenue Current, Total | 5.91Cr | - | - | - | - | |||||
Other Current Liabilities | 39.2L | 54.27L | 96.65L | 1.01Cr | 1.03Cr | |||||
Total Current Liabilities | 10Cr | 7.09Cr | 12Cr | 18Cr | 52Cr | |||||
Long-Term Leases | 77.85L | 11.82L | 21.52L | 4.11Cr | 2.83Cr | |||||
Deferred Tax Liability Non Current | - | - | 1.24Cr | - | 5.9Cr | |||||
Other Non Current Liabilities | 1T | 1T | - | - | - | |||||
Total Liabilities | 11Cr | 7.21Cr | 14Cr | 22Cr | 61Cr | |||||
Common Stock, Total | 17.61L | 17.63L | 17.66L | 17.68L | 17.73L | |||||
Additional Paid In Capital | 56Cr | 57Cr | 58Cr | 59Cr | 61Cr | |||||
Retained Earnings | 23Cr | 22Cr | 46Cr | 31Cr | 135.14Cr | |||||
Comprehensive Income and Other | 10L | 10L | 10L | 10L | 8L | |||||
Total Common Equity | 79Cr | 79Cr | 104.66Cr | 89Cr | 196.71Cr | |||||
Total Equity | 79Cr | 79Cr | 104.66Cr | 89Cr | 196.71Cr | |||||
Total Liabilities And Equity | 90Cr | 86Cr | 118.61Cr | 111.17Cr | 257.52Cr | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 8.81Cr | 8.81Cr | 8.83Cr | 8.84Cr | 8.86Cr | |||||
ECS Total Common Shares Outstanding | 8.81Cr | 8.81Cr | 8.83Cr | 8.84Cr | 8.86Cr | |||||
Book Value / Share | 8.96 | 8.92 | 11.85 | 10.13 | 22.19 | |||||
Tangible Book Value | 79Cr | 79Cr | 104.66Cr | 89Cr | 196.71Cr | |||||
Tangible Book Value Per Share | 8.96 | 8.92 | 11.85 | 10.13 | 22.19 | |||||
Total Debt | 1.59Cr | 1Cr | 49.79L | 5.42Cr | 4.41Cr | |||||
Net Debt | -83Cr | -80Cr | -110.66Cr | -72Cr | -214.64Cr | |||||
Debt Equivalent Oper. Leases | - | - | - | - | - | |||||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |||||
Machinery, Total | 3.98Cr | 5.03Cr | 5.71Cr | 7.25Cr | 8.27Cr | |||||
Full Time Employees | 49 | 61 | 88 | 107 | 129 |
- Stock Market
- Equities
- BIOA B Stock
- Financials BioArctic AB
- Balance Sheet
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















